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Background: Human papillomavirus (HPV) infection plays an etiological role in the development of cervical
dysplasia and cancer. Amplification of human telomerase gene (hTERC) and over expression of telomerase were
found to be associated with cervical tumorigenesis. This study was performed to analyze genomic amplification of
hTERC gene, telomerase activity in association with HPV infection in different stages of cervical intraepithelial
neoplasia (CIN) and cervical cancer. We were studying the role of hTERC in the progression of uterine cervical
dysplasia to invasive cancer, and proposed an adjunct method for cervical cancer screening.
Methods: Exfoliated cervical cells were collected from 114 patients with non neoplastic lesion (NNL, n=27), cervical
intraepithelial neoplasia (CIN1, n=26, CIN2, n=16, CIN3, n=24) and cervical carcinoma (CA, n=21), and analyzed for
amplification of hTERC with two-color fluorescence in situ hybridization (FISH) probe and HPV-DNA with Hybrid
Capture 2.
From these patients, 53 were taken biopsy to analyze telomerase activity by telomeric repeat amplification protocol
(TRAP) and expression of human telomerase reverse transcriptase (hTERT), with immunohistochemistry (IHC). All
biopsies were clinically confirmed by phathologists.
Results: Amplification of hTERC was significantly associated with the histologic diagnoses (p<0.05). The positive
correlation was found between the level of hTERC amplification and histologic grading of dysplasia (CIN2/3 from
CIN1 or normal, P=0.03). A profounding increase in the accumulation of HPV and hTERC positive cases was
observed in the CIN3 subgroup compared with the CIN2 group, 25% versus 62.96%, respectively (p=0.007).
Conclusions: hTERC ampliffication can be detected with FISH technique on exfoliated cervical cells. Amplification
of hTERC and HPV infection are associated with more progressive CIN3 and CA. The testing of hTERC amplification
might be a supplementary to cytology screening and HPV test, especially high-risk patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1857134686755648.
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Cervical cancer (CC) is the second leading cause of can-
cer deaths in women, with more than 80% of these oc-
curring in developing countries that have limited access
to screening programs. It is estimated that 12,170
women will develop cervical cancer and about 4,220
women will die from cervical cancer in the United States
during 2012 [1]. And in China, the mortality rate of cer-
vical cancer ranged from 2 to 4 per 105 population in
urban areas, 0 to 7 per 105 population in rural areas
during the period of 1996 to 2005 [2]. Remarkably, it al-
ways takes about ten years to arise from precancerous
lesion to invasive cervical cancer. For this reason, the ef-
fective screening of precursor lesion is of great import-
ance, which makes cervical cancer preventable and
curable. Cytological examination and HPV test are the
most widely applied screening methods for CC and its
precursor (cervical intraepithelial neoplasia, CIN) lesion.
Although the implementation of the Papanicolaou test
has been in routine, the test has limited accuracy not
likely to be improved with enhanced collection and
screening procedures. Specifically, the inability to dis-
tinguish high-grade CIN with potential possibility of
progression to invasive cancer from pathologically insig-
nificant or regressing dysplasia contributes to overtreat-
ment, whereas false-negative results could not been
eliminated. Furthermore, although 95% of patients with
precancerous lesions harbour oncogenic HPV, only a
small fraction of these eventually progresses to invasive
carcinoma (invCA) [3]. Progression of a high-risk HPV
infected CIN lesion to invCA is a result of further spe-
cific genetic alterations within the host cell genome.
One of the consequences that are crucial for tumor de-
velopment is an increased activity of telomerase.
Telomerase is a ribonucleoprotein enzyme complex
that adds 50-TTAGGG-30 repeats onto the ends of
human chromosomes, providing a telomere maintenance
mechanism for about 90% of cancers [4]. Telomerase
consists of several subunits, including hTERC that serves
as a template during telomere elongation and a catalytic
subunit, human telomerase reverse transcriptase
(hTERT), which has reverse transcriptase activity. The
amplifying of hTERC gene can stop cell apoptosis, con-
sequently leading to tumor occurrence. Now we know
that the detection of gain of hTERC may make clear dis-
tinguish between cytologically low-grade precancerous
lesions and high-grade lesions, reaching sensitivity and
specificity of over 90% [5,6].
Tumorigenesis is a complex phenomenon, whose
manifestations may appear simultaneously on multiple
levels, the genomic, proteomic, and functional alterna-
tion. The correlation between telomerase activation dur-
ing cellular immortalization and in tumor progression
suggests that telomerase activation is required for tumorgrowth. Moreover, telomerase activity is dependent on
the expression of 2 main core component genes, hTERT
and hTERC. This has prompted a large number of stud-
ied addressing telomerase activity using TRAP assay
[7,8], amplification of hTERC using in situ hybridization
[5,6,9-12] or expression of hTERT using IHC in CC and
CIN lesions [13-15]. Cluster analysis between methods
applied to CIN have shown that each level (phenotype,
genotype, progression) should not be studied by itself, as
there may be causal or linear relationships between
them, which could explain more extensively and accur-
ately the tumorigenesis pathway as a dynamic process
[16]. Until now, however, there is no one study that has
been designed to detect these three biomarkers in one
research in clinical samples from CC and CIN lesions.
In this study, we observed, in a large sample scale, amp-
lification of hTERC for progression from normal cervical
tissues to dysplastic lesions and to invasive carcinomas in
Chinese women. And we investigated gain of hTERC, ex-
pression of hTERT, and telomerase activity, and assessed
associations among them. In addition, we assessed gain of
hTERC in relation to physical status of HR-HPV infection.
The results were analyzed to gain insights into the poten-
tial possibility for future clinical applications.
Materials and methods
Samples and cytological screening
Total of 114 outpatient or inpatient patients, visiting
physician office at the Department of Obstetrics and
Gynecology of West China Second University Hospital,
Sichuan University from year 2007 to 2008, were
included in this study with colposcopy-directed biopsy
or hysterectomy. All participants voluntarily signed the
consent form and completed a questionnaire. All
patients had been swapped to get exfoliated cervical
cells, which were collected by saline, for FISH test. Cell
samples also had been taken for high-risk HPV HC2 test
in the Prenatal Diagnosis Center, West China Second
University Hospital, Sichuan University, China. Biopsy
tissues from 53 patients were taken during entry colpos-
copy (EC) or surgery. Each tissue was divided into two
parts, one was freezed in −70°C immediately, and an-
other fixed in 10% neutral buffered formaldehyde solu-
tion for embedding in paraffin.
The histological diagnosis and grading of cervical can-
cers was established according to the guidance of Inter-
national Federation of Gynecology and Obstetrics.
Cervical cytology and histology were initially diagnosed
by pathologists at the Center and then reviewed by a
panel of expert pathologists. Histological diagnosis was
made based on biopsy, endocervical curettage, and/or
excision procedure. All 114 samples consisted of 27 nor-
mal or inflammatory specimens, 26 CIN1, 16 CIN2, 24
CIN3, and 21 invasive cervical carcinomas. The latter
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adenocarcinomas and 1 minimal deviation adenocarcin-
oma. HPV DNA testing was performed, blind to histolo-
gists, in the local Clinical Laboratory, using Hybrid
Capture 2 (HC2, Digene Corporation, Gaithersburg,
MD, USA). The normal group, as the control, was
matched for age and ethnicity/race with study groups.
Fluorescence in situ hybridization (FISH) for hTERC
The specific hTERC gene probe and the reference probe,
centromer enumeration probe for chromosome 3(CEP3),
were directly labeled with Spectrum Red_ and Spectrum
Green_ fluorophore-conjugated dUTP provided by GP
medical Corporation, China. FISH was performed on
slides fixed with Carnoy fixing solution. After overnight
hybridization at 42°C, slides were washed three times
in 50% formamide/2× SSC at 46°C for 5minutes, fol-
lowed by washed in 2× SSC (46°C, 10 minutes) and 0.1%
NP40 in 2× SSC (46°C, 5 minutes). The slides were
stained with nuclear stain (DAPI) and evaluated under a
Zeiss epifluorescence microscope (Zeiss, Oberkochen,
Germany Fluorescence Microscope Company) equipped
with the corresponding wavelength filter, CCD camera,
and image capturing and analyzing system. Signal copy
numbers of both hTERC and 3q marker were counted
from at least 200 nonoverlapping nuclei cells per case by
two trained technologists blindly. Cases were considered
positive for the hTERC assay when more than 5.8%,
which amounts to mean value plus 3 fold of standard
deviation of percentage of hTERC amplification cells in
NNL group, of the cells exhibited a hTERC signal num-
ber more than 2. hTERC signals with the same number
of CEP3 marker signals per nucleus in more than 80% of
cells were considered normal [17].
Immunohistochemistry for hTERT
Immunohistochemical staining for the hTERT expres-
sion was completed following standard IHC procedures.
In brief, the 5-μm paraffin sections cut on poly-L-lysine-
coated microscopy slides were first deparaffinized and
rehydrated in graded alcohols. The sections were heated
in citrate buffer (0.01 M, pH 6.0, DAKO Target Retrieval
Solution) in a microwave oven (95°C, 18 min), followed
by blocking the non-specific binding sites with normal
rabbit serum. Sections were incubated with the primary
antibody, antihuman hTERT antibody (PC563) (EMD
Biosciences, Merck KGaA, Darmstadt, Germany) in a
humidified chamber over night at 4°C (dilution 1:40).
This purified rabbit polyclonal (IgG) antibody has been
raised against the synthetic peptide corresponding to
amino acids 348–358 of human hTERT, and recognizes
a 128 kDa human hTERT protein. Slides were then pro-
cessed with universal LSAB2-2 single reagents (peroxid-
ase) kit (Dako), and expression of hTERT was localizedby incubation with DAB (diaminobenzidine). As a final
step, the slides were stained with a light hematoxylin
counterstaining. Negative controls were similarly pro-
cessed by omitting the primary antibody, and biopsies
from breast cancer were used as positive controls.
TRAP-PCR for quantification of telomerase activity
Biopsy samples were stored at −70°C. The extraction of
telomerase protein and evaluation of its activity were mea-
sured by the telomeric repeat amplification protocol
(TRAP) method using the TRAPeze_ XL telomerase de-
tection kit (Chemicon International, Inc., Temecula, CA),
as described previously [13]. Briefly, extracts from 40 to
100 mg of frozen cervical tissues were homogenized in ap-
proximately 100–200 μl of CHAPS lysis buffer. After 30
min of incubation on ice, the suspensions were centri-
fuged at 12,000g for 20 min at 4°C, after which the super-
natant was frozen rapidly and stored at −70°C. Aliquot of
extract containing 1μg of protein was used for each assay.
The PCR condition was as follows: After 30 min for tel-
omerase extension in 30°C, 95°C for 5 min to activate the
Taq polymerase; 36 cycles of 94°C for 30 s, 55°C for 30 s,
and 72°C for 60 s; an extension at 72°C for 3 min and then
at 55°C for 25 min; finally a 4°C incubation. A fluorescent
plate reader (Wallac 1420 ARVOsx, Perkin-Elmer,Welles-
ley, MA) was used to detect the levels of fluorescein and
sulphorhodamine. The level of telomerase activity was
expressed as total product generated (TPG) units. All
samples were run in duplicate. A reaction mixture with
2μl of CHAPS lysis buffer instead of sample extract was
used as the negative control.
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware packages (SPSS for Windows, version 15.0). Fisher’s
exact test was used to compare the frequency of hTERC
gene–amplified samples in the defined biopsy groups.
Chi-square test, one-way analysis of variance (ANOVA)
and logistic correlation analysis were used when appro-
priate. In all tests, values of P < 0.05 were regarded sta-
tistically significant.
Results
Genomic amplification of hTERC
FISH analysis was performed on 114 cervical exfoliated
specimens, and 11 of them were excluded because of the
lack of hybridization signals or too few cells on slides.
The percentage of successfully hybridized samples was
96.49%. The results of the enumerations were summar-
ized in Table 1 and Figures 1, 2.-A, B, C shows represen-
tative hybridizations. This analysis reveals that the
average number of hTERC-positive cases increases ac-
cordingly with escalating levels of dysplasia. The per-
centage of hTERC-positive cases found on slides from
Table 1 Summary of hTERC amplification according to histology diagnosis
Histology Dx Number of
cases
No. of cases with hTERC
amplification (%)*
Mean of cell number with
hTERC amplification
NNL 26 0 1.058
CIN1 19 4 (21.1%) 5.132
CIN2 12 6 (50%) 6.083
CIN3 27 22 (81.5%) 11.093
CA 19 19 (100%) 21.105
Dx, diagnosis; NNL, non neoplastic lesion; CIN, cervical intraepithial neoplasia; CA, cervical carcinoma.
*A case of hTERC amplification was defined as more than 5.8% of the cells showed a pattern when number of hTERC signal was more than 2.
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CIN2 and CIN3 samples, however, revealed a statically
significant increase with hTERC gain per slide (p=0.022,
0.009, respectively).
Statistical analysis showed that in 28 cases diagnosed
as LSIL on cytology, the positive cases with hTERC amp-
lification differentiated those histological diagnosed as
high-grade dysplasia (CIN2/3) from those diagnosed as
low-grade dysplasia (CIN1) or NNL (P=0.03) (Figure 3).hTERT protein expression
We found biopsies with normal epithelium were com-
pletely negative for hTERT, or at maximum, showing
scattered positive cells within the parabasal layers.
Somewhat more hTERT positive staining was observed
in metaplastic squamous epithelium, but only in single
cells. The staining pattern was completely different in
CIN lesion; there was usually full thickness of the lesion
demonstrated positive hTERT expression, varying in in-
tensity from weak to extremely strong. Positive hTERT
staining was mostly confined to nuclei only, but onFigure 1 Graph depicting the distribution of hTERC
amplification by histological diagnosis. *The group of CIN2 and
CIN3 samples revealed a statically significant increase with hTERC
gain per slide (p=0.022, p=0.009, respectively).several occasions, also weak cytoplasmic expression was
detectable (Figure 2-D, E, F).
Telomerase activity
The telomerase activity in different histological groups is
summarized in Figure 4. We found that telomerase ac-
tivity was higher in CIN3/CA compared to control nor-
mal or CIN1/2(P=0.00); The levels of telomerase activity
were 0.473±0.259 in normal group, 1.104±0.347 in CIN1,
1.350±0.347 in CIN2, 3.342±0.194 in CIN3, 4.318±0.274
log10[TPG] in CA. Therefore, we speculate that variations
in telomerase activity among individual histology groups
could indicate to their severity of dysplasia.
We looked for an association of hTERC gain with the
telomerase activity using logistic correlation analysis.
The Pearson correlation is 0.594 (P=0.000).
Association of the hTERC amplification with HPV Infection
114 cervical specimens included in the study had previ-
ously been analyzed for the presence of HPV DNA by
HC2 test. 77 of them were found infected with high-risk
HPV types. The results for HPV-positive, hTERC-
amplification and both HPV and hTERC positive ratio in
cervical specimens grouped by histology diagnosis were
shown in Figure 5.
This analysis reveals that both HPV-infected positive
ratio and hTERC-amplification positive ratio increase ac-
cordingly with escalating levels of dysplasia. hTERC
positive ratio of patients classified as histologically NNL
was just 3.85%, whereas those of classified CIN3 and CA
were 81.5% and 100%, respectively. The difference of the
hTERC positive ratio in CIN2 and CIN3 categories was
statistically significant (p=0.009).
The HPV-infected status was also determined using
HC2 for all of the different histological categories. The
results revealed that 23.08% of high-risk HPV positive
patients were found in NNL group, and 78.95% in CA
group. There was no statistically difference to be observed
in CIN2/3/CA groups (p=0.232, 0.297, respectively).
To further investigate the relationships between HPV
infection and hTERC amplification, we analyzed the data
combined. Not all genomic abnormal cases were found
Figure 2 Double-color probe set for the detection of the hTERC gain and immunohistological detection for hTERT in cervical dysplasia.
A. interphase FISH shows a normal signal pattern containing two copies each of the hTERC ( red) and CEP3 (green) (X630). B. interphase FISH
shows increased number of signals for hTERC (red) compared to CEP3(green) (X630) C. interphase FISH shows gain of both hTERC (red) and CEP3
(green) gains in the larger cells (X630). D. Weakly hTERT positive cells are found in the suprabasal cell layers. (IHC for hTERT, original
magnification× 400) E. A high-grade CIN3 lesion, where hTERT positive cells are found throughout the full thickness of the epithelium. (IHC for
hTERT, original magnification×400) F. An invasive squamous cell carcinoma with strong hTERT expression. The staining intensity varies from weak
to intense dark brown, indicating that the expression levels of hTERT vary from cell to cell. (IHC for hTERT, original magnification× 400).
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showed signs of hTERC amplification. Over all, the ad-
vancement of the disease correlated well with the
increased genomic instability in HPV-infected cases. AFigure 3 Box-plot of number of cases with/without hTERC
amplification by biopsy diagnosis for patients with a cytologic
diagnosis of LSIL. The number of hTERC amplification positive
cases was differentiate between NNL+CIN1 group and CIN2 + CIN3
group. (P=0.03).marked increase in the accumulation of both HPV&
hTERC positive cases was observed in the CIN3 sub-
group compared with the CIN2 group, 62.96% versus
25%, respectively. The difference was statistically signifi-
cant (p=0.007). Interestingly, the subgroup of patients
with NNL diagnosis did not have any case to be shown
as both HPV and hTERC positive.
Discussion
Genomic amplification of the hTERC in cytologic speci-
mens was significantly correlated with the severity of dys-
plasia. Patients with biopsy diagnoses of CIN or CA had
significantly higher percentages of cells with extra copies
of hTERC than did patients with a normal biopsy diagno-
sis. This test may be a complementary to regular screening
methods to detect patients with high-grade lesions.
Several authors have shown that the percentage of
cells with gain of hTERC copy number increased with
the severity of dysplasia [5,6,9-12,18]. Heselmeyer et al.
Figure 4 Quantification of telomerase activity in different
biopsy groups. The vertical axis represents the log10 [TPG] levels for
telomerase activity in the samples. Telomerase activity showed no
difference neither in CIN1 to NNL groups (P=0.153), nor in CIN2 to
CIN1 groups (p=0.619). CIN3 exhibited high levels of telomerase
activity compared with CIN2 group (P=0.000). Samples with CA
expressed higher levels of telomerase activity than with CIN3
(P=0.006).
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visualization of chromosomal copy number changes and
found 63% of the HSIL( CIN2) lesions and 76% of the
HSIL(CIN3) lesions showed extra copies of 3q [5]. In an-
other paper, the same group designed a retrospective
study set to 59 previously stained Pap smears, and pro-
posed that gains of chromosome arm 3q play a crucial
role in the progression of severe dysplasia/carcinoma in
situ to invCA [6]. One study else on tissue sections also
showed that 3q gain was detected in all of 12 cervical
adenocarcinomas [8]. In our study, we analyzed a series
of 114 Chinese women. Based on intensive test of exfo-
liated cell samples, our data show that extra copy num-
bers of hTERC present in 50% of CIN2, 81.5% of CIN3
and 100% of CA, no matter of what kind of histology
type, of cases respectively. This result was similar toFigure 5 Gray-scale graph labels the percentage of positive cases in i
black, demonstrates the increasing percentage of positive cases.other studies in China [18,19]. The percentage of suc-
cessfully hybridized samples was 96.49%, considerably
higher than in the series of Pap smears [5].
Hongxiu Han et al. [20] suggested helpful biological
markers would be in need of distinguishing CIN1 from
CIN2/3. The expression of hTERT was evaluated as a
potential marker of the high-grade premalignant CIN 2/
3 lesions [14]. A recent study showed that overexpres-
sion of hTERC and hTERT together in vitro greatly
induced telomerase activity and telomere length elong-
ation, while stable overexpression of either hTERC or
hTERT alone induced telomerase activity and telomere
length elongation to a lesser extent [21]. Consistent with
this study, several studies also highlighted the fact that
both telomerase components restrict telomerase activity
and telomere length in vitro, suggesting that the tumori-
genic effects of hTERT overexpression are reliant on
hTERC expression and in fact hTERT overexpression in
an hTERC deficient background has anti-tumourigenic
effects [22-24]. Our data showed that in cervical intrae-
pithelial lesions, levels of hTERC amplification were cor-
related with telomerase activity and hTERT expression.
Furthermore, comparing with biopsy procedure, exfo-
liated cells samples used for hTERC testing in our study
were easier to get from patients with a concurrent phys-
ical examination. From this point of view, we suggest
there is the potential value of detecting hTERC gain by
FISH method for distinguishing between lesions with
and without progression to in situ or invasive malig-
nancy of uterine cervix.
In a previous study by Sokolova I et al. [11], 235
liquid-based preparation from cervical specimens were
analyzed for aberrations of 3q26 using a commercially
two-color FISH probe. They found in cases diagnosed as
LSIL on cytology, the percentage of cells with gain of
3q26 did not differentiate those histologically diagnosed
as high-grade dysplasia (CIN2/3) from those diagnosed
as low-grade dysplasia (CIN1). Unfortunately, only a fewndividual groups. The color turns from white to gray, and lastly to
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that study. As shown in our study, we not only analyzed
abnormal cells on exfoliated cervicovaginal preparations
for gain of hTERC using a FISH probe similar to that
used by Nancy P et al. [12], but also each case had both
HPV testing and concurrent biopsy results. In cases of
LSIL, gain of 3q26 differentiated those lesions that had
CIN2/3 on biopsy from those that did not.
It is not sufficient for HPV screening assays by itself in
predicting the progression from atypical or mild dyspla-
sia to high-grade lesion and subsequently to cancer, be-
cause this screening is lack of a high positive predictive
value for the presence of dysplasia. Furthermore, a re-
port indicated that some kind of cervical cancer, such as
minimal deviation adenocarcinoma, was not associated
with high-risk HPV [25]. Qisang et al. [26] reported a
significant positive correlation between positive hTERC
gain and HR-HPV infection, histopathologic lesions (all
P<0.01) in patients with cervical disease. Our study
demonstrates that there are 23% HPV-infected positive
cases in NNL, and 78.95% in CA group. From the gray-
scale graph, we can see the HPV position ratio increase
according to the severity of dysplasia. However, the pre-
dictive value of hTERC amplification test is much better
than HPV test. Only 3.85% hTERC amplification positive
ratio was observed in NNL group, and 100% in CA
group, including two cases of minimal deviation adeno-
carcinoma. If combined these two tests together, it
seems like much better than any one of them alone. In
NNL group, there was not any case with both HPV and
hTERC positive. From the clinical perspective, we
hypothesize that hTERC gain, combining with testing of
HPV infection by HC2, might have a very significant
clinical application.
In summary, this study presents gain of hTERC in
exfoliated cervicovaginal epithelial specimen and sug-
gests a role of the factor in the biology of cervical can-
cer. Potential clinical usefulness of the hTERC FISH
would be to distinguish patients with clinically signifi-
cant cervical lesions from those that are insignificant
lesions with a high risk of progression from those with a
low risk of progression or an adjunct to cytology screen-
ing, especially in HPV-infection patients. However, more
studies are needed to determine the application of
hTERC gain in surveillance and prognosis of invasive
cervical cancer.
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